The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

A decision is expected in the fourth quarter of 2025.

SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...

Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Lotte Bjerre Knudsen lives comfortably in this pleasant, but not showy, £900,000 apartment in central Copenhagen with her ...

Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like ...

The Trump administration this April scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, ...